Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gan & Lee’s GLP-1 Candidate Posts Solid Results for Weight Loss

publication date: Jul 23, 2024

Gan & Lee Pharma posted impressive weight loss results in a China Phase IIb trial of its long-acting GLP-1 receptor agonist (GLP-1 RA). Overweight and obese patients were treated at one of four dosing levels. After 30 weeks, the results varied from 11.15% average weight loss in the lowest dose to 17.79% at the highest doses. Patients were treated every two weeks. Gan & Lee, a Beijing company that focuses on diabetes therapies, was the first Chinese company to develop a domestic insulin analog drug. More details....

Stock Symbol: (SHA: 603087)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here